Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Tart Cherry Supplementation and Women's Bone Health Study

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
リンクがクリップボードに保存されます
状態完了
スポンサー
Oklahoma State University
共同編集者
Cherry Marketing Institute Research Committee

キーワード

概要

In spite of aggressive approaches to prevent and treat osteoporosis, it remains one of the most costly and debilitating diseases associated with aging. The pursuit of alternative approaches for preventing bone loss has included the investigation of a number of promising plant-based foods that can be incorporated into the diet. This project is an extension of our pre-clinical studies with tart cherry, designed to determine whether the findings from our animal study can be extended to humans. Thus, the purpose of this project is to investigate the dose-dependent effect of tart cherry juice consumption on biomarkers of bone metabolism in women, aged 65-80 years. The hypothesis to be tested is that three months of tart cherry supplementation will improve bone biomarkers in a dose-dependent manner. Moreover, these improvements in bone metabolism will correspond to a decrease in markers of inflammation and oxidative stress.

説明

Tart cherries are an excellent course of phenolic compounds and anthocyanins, and in pre-clinical studies have been shown to prevent age-related bone loss. Based on these findings, this pilot study was designed to investigate the effects of three months of tart cherry juice supplementation on improving markers of oxidative stress and bone metabolism in older women. Women (n=30), aged 65-80 yrs, will be recruited for the study and randomly assigned to one of two doses of tart cherry juice (8 or 16 fl oz) per day prepared from a Montmorency cherry concentrate (King Orchards, Central Lake, MI). Study participants will complete two study visits to the Nutritional Sciences Clinical Research Center. At the first visit, informed consent will be obtained and relevant medical history and anthropometric measures will be taken by the research team. A blood draw will be performed to assess baseline, biochemical markers of bone metabolism and inflammation as well as indicators of oxidative status. A physical activity and food frequency questionnaire will be completed by each study participant. Whole body, hip and spine bone density (DXA) scan will be performed by certified bone densitometrist. A 3-month final visit will be scheduled for all study participants in which most of the procedures described at baseline (except DXA) will be repeated. Change in primary and secondary outcome measures (i.e., bone, inflammation and oxidative stress biomarkers) will be assessed.

日付

最終確認済み: 10/31/2019
最初に提出された: 11/09/2019
提出された推定登録数: 11/14/2019
最初の投稿: 11/17/2019
最終更新が送信されました: 11/14/2019
最終更新日: 11/17/2019
実際の研究開始日: 06/05/2017
一次完了予定日: 05/30/2018
研究完了予定日: 05/30/2018

状態または病気

Osteoporosis, Postmenopausal
Osteoporosis, Age-Related

介入/治療

Dietary Supplement: tart cherry juice concentrate is a commercial product provided by King Orchards (Central Lake, MI)

段階

-

アームグループ

介入/治療
Active Comparator: Dose 1
Participants consume 8 fl oz of tart cherry juice per day.
Experimental: Dose 2
Participants consume 2 x 8 fl oz of tart cherry juice per day.

適格基準

研究の対象となる年齢 65 Years に 65 Years
研究に適格な性別Female
健康なボランティアを受け入れるはい
基準

Inclusion Criteria:

- Women, 65-80 years of age

- Capacity to give informed consent

Exclusion Criteria:

- Hormone replacement therapy in the 3 months prior to starting the study

- Bisphosphonates in the 3 months prior to starting the study

- Raloxifene in the 3 months prior to starting the study

- Intermittent parathyroid hormone in the 3 months prior to starting the study

- Growth hormone or steroids in the 3 months prior to starting the study

- Osteoporosis

- Renal disease

- Cancer

- Cardiovascular disease

- Diabetes

- Respiratory disease

- Gastrointestinal diseases

- Liver disease

- Other chronic conditions that could affect bone metabolism

結果

主な結果の測定

1. Bone-specific alkaline phosphatase (U/L) [Change from baseline to final visits (3 month intervention)]

Bone formation marker

2. Tartrate resistant acid phosphatase (U/L) [Change from baseline to final visits (3 month intervention)]

Bone resorption marker

二次的な結果の測定

1. C-reactive protein (mg/L) [Change from baseline to final visits (3 month intervention)]

Marker of inflammation

2. Thiobarbituric acid reactive species (TBARS) (U/L) [Change from baseline to final visits (3 month intervention)]

Marker of oxidative stress

Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge